Yitian Lang

4PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 19, 2025
Cost-effectiveness analysis of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy for advanced HER2-negative gastric or gastro-esophageal junction cancer.

Yitian Lang, Weican Cao, Yan Lin

|Sep 14, 2023
Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.

Yitian Lang, Yan Lin, Dan Li

|Dec 19, 2022
Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.

Yitian Lang, Bin Wu, Xiaoyan Liu

|Apr 28, 2022
Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting.

Yitian Lang, Bin Wu, Zhilin Sun

Pageof 1

Frequent Collaborators